Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C77896
http://purl.obolibrary.org/obo/NCIT_C77896
|
|---|---|
| Preferred Name | Tucatinib |
| Definitions |
An orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity. Tucatinib selectively binds to and inhibits the phosphorylation of ErbB-2, which may prevent the activation of ErbB-2 signal transduction pathways, resulting in growth inhibition and death of ErbB-2-expressing tumor cells. ErbB-2 is overexpressed in a variety of cancers and plays an important role in cellular proliferation and differentiation.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also called HER2) with potential antineoplastic activity. Tucatinib selectively binds to and inhibits the phosphorylation of ErbB-2, which may prevent the activation of ErbB-2 signal transduction pathways, resulting in growth inhibition and death of ErbB-2-expressing tumor cells. ErbB-2 is overexpressed in a variety of cancers and plays an important role in cellular proliferation and differentiation. |
|---|---|
| prefLabel | Tucatinib
|
| label | Tucatinib
|
| NCI_META_CUI | CL383576
|
| PDQ_Closed_Trial_Search_ID | 594366
|
| code | C77896
|
| Has_Target | |
| prefixIRI | NCIT:C77896
|
| in_subset |
See more
See less
|
| Display_Name | Tucatinib
|
| Preferred_Name | Tucatinib
|
| FDA_UNII_Code | 234248D0HH
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Tucatinib
|
| CAS_Registry | 937263-43-9
|
| NCI_Drug_Dictionary_ID | 594366
|
| Legacy Concept Name | ErbB-2_Inhibitor_ARRY-380
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 594366
|
| Accepted_Therapeutic_Use_For | in combination with trastuzumab and capecitabine, for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |